卡培他滨联合多西他赛、表柔比星和环磷酰胺辅助治疗早期乳腺癌:随机临床FinXX试验
FinXX试验探索性分析纳入芬兰和瑞典1500例早期乳腺癌女性,随机接受多西他赛序贯环磷酰胺、表柔比星、氟尿嘧啶(T+CEF)或多西他赛联合卡培他滨序贯环磷酰胺、表柔比星、卡培他滨(TX+CEX)。中位随访10.3年,两组无复发生存(RFS)和总生存无显著差异;三阴性乳腺癌亚组中TX+CEX较T+CEF改善生存结局。
要点
- TX+CEX与T+CEF相比未显著延长RFS或总生存。
- 三阴性乳腺癌亚组中TX+CEX的RFS和生存优于T+CEF。
- 该获益来自探索性亚组分析。
核心结论
- 含卡培他滨方案与仅含标准药物的方案相比未延长RFS或生存。
- 探索性亚组分析中三阴性乳腺癌患者接受含卡培他滨方案生存结局较好。
研究设计与样本
- 多中心FinXX随机临床试验的探索性分析,2004年1月27日至2007年5月29日在芬兰和瑞典入组1500例女性。
- 约一半接受3周期多西他赛序贯3周期环磷酰胺、表柔比星、氟尿嘧啶(T+CEF),另一半接受3周期多西他赛联合卡培他滨序贯3周期环磷酰胺、表柔比星、卡培他滨(TX+CEX)。
- 随机分配后747例接受T+CEF,753例接受TX+CEX;5例被排除在意向治疗人群外(3例随机时已有明显远处转移,2例撤回知情同意)。
- 剩余1495例患者入组时中位年龄53岁;157例(11%)腋窝淋巴结阴性;1142例(76%)ER阳性;282例(19%)HER2阳性。
- 随机分配后中位随访时间10.3年。
主要发现
- 两组RFS无显著差异(HR 0.88,95%CI 0.71-1.08,P=0.23)。
- 两组总生存无显著差异(HR 0.84,95%CI 0.66-1.07,P=0.15)。
- 乳腺癌特异性生存趋向 favoring 卡培他滨组(HR 0.79,95%CI 0.60-1.04,P=0.10)。
- 三阴性乳腺癌亚组中TX+CEX较T+CEF改善RFS(HR 0.53,95%CI 0.31-0.92,P=0.02)和生存(HR 0.55,95%CI 0.31-0.96,P=0.03)。
关键数值与推荐
- RFS:T+CEF组 vs TX+CEX组 HR 0.88(95%CI 0.71-1.08,P=0.23)。
- 总生存:T+CEF组 vs TX+CEX组 HR 0.84(95%CI 0.66-1.07,P=0.15)。
- 乳腺癌特异性生存:HR 0.79(95%CI 0.60-1.04,P=0.10),趋向 favoring 卡培他滨组。
- 三阴性乳腺癌亚组RFS:TX+CEX较T+CEF HR 0.53(95%CI 0.31-0.92,P=0.02)。
- 三阴性乳腺癌亚组生存:TX+CEX较T+CEF HR 0.55(95%CI 0.31-0.96,P=0.03)。
临床怎么用
- 原文未据此给出推荐。
- 作者指出卡培他滨联合多西他赛、表柔比星和环磷酰胺与仅含标准药物的方案相比未延长RFS或生存。
- 作者报告三阴性乳腺癌患者在探索性亚组分析中接受含卡培他滨方案生存结局较好。
局限性
- 三阴性乳腺癌亚组结果来自探索性亚组分析。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast cancer (TNBC). OBJECTIVE: To investigate the effect of capecitabine on long-term survival outcomes of patients with early breast cancer, particularly in subgroups defined by cancer estrogen receptor (ER) and progesterone receptor (PR) content, and HER2 content (human epidermal growth factor receptor 2). DESIGN, SETTING, AND PARTICIPANTS: This is an exploratory analysis of the multicenter FinXX randomized clinical trial that accrued 1500 women in Finland and Sweden between January 27, 2004, and May 29, 2007. About half received 3 cycles of docetaxel followed by 3 cycles of cyclophosphamide, epirubicin, and fluorouracil (T+CEF), while the other half received 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, epirubicin, and capecitabine (TX+CEX). Data analysis took place between January 27, 2004, and December 31, 2015. MAIN OUTCOMES AND MEASURES: Recurrence-free survival (RFS). RESULTS: Following random allocation, 747 women received T+CEF, and 753 women received TX+CEX. Five patients were excluded from the intention-to-treat population (3 had overt distant metastases at the time of randomization; 2 withdrew consent). The median age of the remaining 1495 patients was 53 years at the time of study entry; 157 (11%) had axillary node-negative disease; 1142 (76%) had ER-positive cancer; and 282 (19%) had HER2-positive cancer. The median follow-up time after random allocation was 10.3 years. There was no significant difference in RFS or overall survival between the groups (hazard ratio [HR], 0.88; 95% CI, 0.71-1.08; P = .23; and HR, 0.84, 95% CI, 0.66-1.07; P = .15; respectively). Breast cancer-specific survival tended to favor the capecitabine group (HR, 0.79; 95% CI, 0.60-1.04; P = .10). When RFS and survival of the patients were compared within the subgroups defined by cancer steroid hormone receptor status (ER and/or PR positive vs ER and PR negative) and HER2 status (positive vs negative), TX+CEX was more effective than T+CEF in the subset of patients with TNBC (HR, 0.53; 95% CI, 0.31-0.92; P = .02; and HR, 0.55, 95% CI, 0.31-0.96; P = .03; respectively). CONCLUSIONS AND RELEVANCE: Capecitabine administration with docetaxel, epirubicin, and cyclophosphamide did not prolong RFS or survival compared with a regimen that contained only standard agents. Patients with TNBC had favorable survival outcomes when treated with the capecitabine-containing regimen in an exploratory subgroup analysis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00114816.
引用
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial. JAMA Oncol. 2017. PMID: 28253390. doi:10.1001/jamaoncol.2016.6120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。